Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$107.28M-34.6%-$111.48M-42.4%-$97.7M-36.0%-$88.31M-40.1%-$79.7M-55.3%
$1M+7.4%$1.02M+21.2%$1.01M+60.1%$975K+124%$931K
$21.78M+70.4%$18.86M+84.2%$16.37M+104%$14.82M+160%$12.78M
-$80.3M-19.0%-$87.47M-34.9%-$77.22M-27.1%-$76.17M-53.1%-$67.45M
$411K-74.7%$616K-74.4%$673K-81.4%$679K-80.8%$1.62M
-$170.56M-$187.47M
$271.31M+70.2%$270.79M+21.4%$270.48M-$51K$159.37M
$20.45M-$4.16M
-$80.71M-16.8%-$88.09M-31.0%-$77.89M-21.0%-$76.85M-44.2%-$69.07M

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Rapport Therapeutics, Inc. generate?
Rapport Therapeutics, Inc. (RAPP) generated -$80.3M in operating cash flow over the trailing twelve months.
What is Rapport Therapeutics, Inc.'s free cash flow?
After $411.0K of capital expenditures, Rapport Therapeutics, Inc.'s free cash flow was -$80.7M over the trailing twelve months, down 16.8% year over year.
Where does Rapport Therapeutics, Inc.'s cash flow data come from?
Every line is extracted from Rapport Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.